Citations

Clear

16281 citation(s) found for "Yu, David".

Identify Non-mutational p53 Functional Deficiency in Human Cancers
Li, Qianpeng , Zhang, Yang , Luo, Sicheng , Zhang, Zhang , Oberg, Ann L. , Kozono, David , Lu, Hua , Sarkaria, Jann N. , Ma, Lina , Wang, Liguo , Kozono, David E , Wang, Liguo , Sarkaria, Jann N

Mayo Clinic

Genomics, Proteomics & Bioinformatics | September 26, 2024 | Volume: 22 | Issue: 5 | Pages: No page available

10.1093/gpbjnl/qzae064 | PMID 39325855 Get It

Abstract An accurate assessment of p53’s functional statuses is critical for cancer genomic medicine. However, there is a significant challenge in identifying tumors with non-mutational p53 inactivation which is not detectable through DNA sequencing. These undetected cases are often misclassified as p53-normal, leading to inaccurate prognosis and downstream association analyses. To address this issue, we built the support vector machine (SVM) models to systematically reassess p53’s functional statuses in TP53 wild-type (TP53WT) tumors from multiple The Cancer Genome Atlas (TCGA) cohorts. Cross-validation demonstrated the good performance of the SVM models with a mean area under the receiver operating characteristic curve (AUROC) of 0.9822, precision of 0.9747, and recall of 0.9784. Our study revealed that a significant proportion (87%–99%) of TP53WT tumors actually had compromised p53 function. Additional analyses uncovered that these genetically intact but functionally impaired (termed as predictively reduced function of p53 or TP53WT-pRF) tumors exhibited genomic and pathophysiologic features akin to TP53-mutant tumors: heightened genomic instability and elevated levels of hypoxia. Clinically, patients with TP53WT-pRF tumors experienced significantly shortened overall survival or progression-free survival compared to those with predictively normal function of p53 (TP53WT-pN) tumors, and these patients also displayed increased sensitivity to platinum-based chemotherapy and radiation therapy.
Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration
Vandebergh, Marijne , Ramos, Eliana Marisa , Corriveau‐Lecavalier, Nick , Ramanan, Vijay K. , Kornak, John , Mester, Carly , Kolander, Tyler, Brushaber, Danielle , Staffaroni, Adam M. , Geschwind, Daniel H., Wolf, Amy , Kantarci, Kejal, Petrucelli, Leonard , Broeck, Marleen Van den , Wynants, Sarah , Baker, Matthew , Borrego‐Écija, Sergi , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kwan, Justin , Litvan, Irene , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ritter, Aaron, Roberson, Erik D. , Snyder, Allison , Sullivan, Anna Campbell, Wint, Dylan , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J. , Rademakers, Rosa , Kantarci, Kejal , Brushaber, Danielle E, Wolf, Amy A, Gendron, Tania F , Van den Broeck, Marleen, Borrego-Écija, Sergi , Appleby, Brian , Barmada, Sami , Bozoki, Andrea C , Darby, Richard Ryan , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Fields, Julie A , Galasko, Douglas , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Huey, Edward D , Irwin, David J , Knopman, David S. , Kwan, Justin Y., Léger, Gabriel C, Litvan, Irene , Onyike, Chiadi , Pascual, Belen , Pressman, Peter S, Roberson, Erik , Tartaglia, Maria Carmela , Wint, Dylan , Heuer, Hilary W , Forsberg, Leah K , Boxer, Adam , Rosen, Howard J , Boeve, Brad , Rademakers, Rosa , Kantarci, Kejal , Ramanan, Vijay K , Corriveau-Lecavalier, Nick , Snyder, Allison , Vandebergh, Marijne , Mester, Carly , Geschwind, Daniel H. , Gendron, Tania F. , Appleby, Brian S. , Clark, David, Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Knopman, David S. , Léger, Gabriel C. , Masdeu, Joseph C , Boeve, Bradley F.

Mayo Clinic

Neurology | September 25, 2024 | Volume: 103 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000209832 | PMID 39321401 Get It

Response to Comment on A Method for Continuous Surgeon Improvement in Rectal Cancer
Merchea, Amit , Dozois, Eric J. , Dozois, Eric, Ferrari, Davide , Violante, Tommaso , Vierkant, Robert A. , Larson, David W.

Mayo Clinic

Annals of Surgery Open | September 25, 2024 | Volume: 5 | Issue: 4 | Pages: e494

10.1097/as9.0000000000000494 | PMID 39711687 Get It

Prognostic value of echocardiographic-derived stroke volume in severe primary mitral regurgitation
Granot, Yoav , Gefen, Sheizaf , Karlsberg, Daniel , Sapir, Orly Ran , Perl, Michal Laufer, Zahler, David , Viskin, Dana , Banai, Shmuel , Havakuk, Ofer , Ran Sapir, Orly, Topilsky, Yan , Havakuk, Ofer , Topilsky, Yan

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | September 25, 2024 | Volume: 26 | Issue: 2 | Pages: 307-312

10.1093/ehjci/jeae249 | PMID 39317663 Get It

Abstract Aims Studies have demonstrated the importance of forward flow, and specifically of stroke volume (SV) and SV index (SVI), as prognostic markers in different cardiovascular diseases. In this study, we aim to evaluate the association between SV and SVI thresholds and prognosis in patients with severe primary mitral regurgitation (MR). Methods and results The association between either SV (<55, 55–70, and >70 mL) or SVI (<30, 30–35, and >35 mL/m2) thresholds and all-cause mortality and heart failure (HF) hospitalizations was examined in a retrospective analysis of 283 patients [60% male, median age 70 years, interquartile range (IQR) 58–82] with severe primary MR, normal left ventricular size and systolic function, and no other significant left-sided valvular abnormalities. Compared with normal values, SV < 55 mL was found to be associated with worse outcomes (hazard ratio 1.8, IQR 1.1–2.8, P = 0.016), whereas SV between 55 and 70 mL was not. A non-significant trend for worse outcomes was noted for SVI < 35 mL/m2 compared with normal SVI. Conclusion In patients with severe primary MR, SV < 55 mL was found to be associated with increased rates of HF hospitalization and all-cause mortality. This easily obtainable parameter may allow for better risk stratification of patients with primary MR.
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard , Cummings, Jeffrey L., Boxer, Adam L., Staffaroni, Adam M. , Knopman, David S., Territo, Paul R. , Arnold, Steven E. , Boeve, Bradley F., Dacks, Penny A. , Diaz, Kristophe , Ewen, Colin, González, María Isabel , Harris, Glenn A., Hoffman, Beth J., Martinez, Terina N. , Nisenbaum, Laura K., Palma, Jose‐Alberto , Quintana, Melanie , Rabinovici, Gil D. , Rohrer, Jonathan D. , Rosen, Howard J., Troyer, Matthew D. , Kim, Doo Yeon , Tanzi, Rudolph E. , Zetterberg, Henrik, Ziogas, Nick, May, Patrick C. , Rommel, Amy, Feldman, Howard H , Palma, Jose-Alberto , Rohrer, Jonathan D , Rabinovici, Gil D , Dacks, Penny , Boxer, Adam L. , Knopman, David S. , Rizzo, Stacey J. Sukoff , Ballard, Clive , Beher, Dirk , Boeve, Bradley F. , Fiske, Brian , McDade, Eric , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | September 24, 2024 | Volume: 20 | Issue: 11 | Pages: 8129-8152

10.1002/alz.14250 | PMID 39316411 Get It

AbstractThe tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.
EP014 A prospective, randomized dose-Finding study of intrathecal morphine and hydromorphone for analgesia after colorectal surgery
Pleticha, Josef, Vinsard, Patrice A , Olsen, David A. , Sviggum, Hans P. , Shawki, Sherief , Vinsard, Patrice , Sharpe, Emily E. , Panchamia, Jason K. , Behm, Kevin T.

Mayo Clinic

ePoster session 1 – Station 3 | September 24, 2024 | Volume: No volume available | Issue: No issue available | Pages: A70.1-A70

10.1136/rapm-2024-esra.87 Get It

Esophageal Expert Development of a Preliminary Question Prompt List for Adults With Eosinophilic Esophagitis: A Modified Delphi Study
Achalu, Sudharshan, Berry, Rani , Joseph, Abel , Bhargava, Meera , Fernandez‐Becker, Nielsen , Chang, Joy W. , Dellon, Evan S. , Hirano, Ikuo , Horsley‐Silva, Jennifer L. , Leiman, David A. , Lynch, Kristle L. , Peterson, Kathryn , Kamal, A. N. , Horsley-Silva, Jennifer, Bredenoord, Albert J. , Falk, Gary W. , Kamal, Afrin N.

Mayo Clinic

Journal of Clinical Gastroenterology | September 23, 2024 | Volume: 59 | Issue: 6 | Pages: 537-541

10.1097/mcg.0000000000002066 | PMID 39312545 Get It

Background: Question prompt lists (QPLs) are structured sets of disease-specific questions intended to encourage question-asking by patients and enhance patient-physician communication. To date, an EoE-specific QPL has not been developed for EoE patients. Aim: To develop a preliminary QPL specific to adults with EoE by incorporating input from international esophageal experts. Methods: Sixteen experts were invited to generate QPL content through a modified Delphi (RAND/University of California, Los Angeles, CA) method consisting of 2 rounds of independent ratings. In round 1, experts provided 5 answers to the prompts “what general questions should patients ask when being seen for EoE?” and “what questions do I not hear patients asking but given my experience, I believe they should be asking?” In round 2, experts rated each question on a 5-point Likert scale, and responses rated as “essential” or “important” (determined by an a priori median threshold of ≥ 4.0) were accepted for the EoE QPL. Results: Ten esophageal experts participated in both rounds. Round 1 generated 100 questions. Questions were combined and modified to reduce redundancy, yielding 57 questions. After round 2, 51 questions (85%) were accepted for inclusion (median value ≥ 4.0) in the final QPL. Questions were then divided into 4 themes based on disease domains: (1) “What is EoE?,” (2) “Treatment Options,” (3) “Follow-up Surveillance and Long-term Risks,” and (4) “Allergy and Genetic Testing.” The largest number of questions covered was “What is EoE?” (16/51 or 31%). Questions with the highest agreement median (5.0) included examples such as “what should I do if I get a food impaction?” and “what are the treatment options?” Conclusion: This is the first preliminary EoE QPL developed in the field of medicine. We hope implementation enhances effective patient-physician communication by encouraging patients to ask relevant questions that experts prioritized. Future studies will aim to modify this communication tool by incorporating patient perspectives
Optimizing the hemodynamics of hand injections in neuroangiography
Bayraktar, Esref Alperen , Bilgin, Cem , Ueki, Yasuhito , Kadirvel, Ramanathan , Brinjikji, Waleed , Cloft, Harry J. , Kallmes, David F. , Bilgin, Cem , Kadirvel, Ram , Kallmes, David F , Bayraktar, Esref Alperen , Li, Jiahui , Cortese, Jonathan

Mayo Clinic

Interventional Neuroradiology | September 23, 2024 | Volume: 30 | Issue: 6 | Pages: 833-838

10.1177/15910199241285944 | PMID 39311020 Get It

Purpose Optimizing the preparation of a 10 ml syringe for manual injection of contrast media can help operators obtain easier and faster injections. This study aims to compare the flow rates of different contrast media injection methods. Methods Different contrast media solutions were compared: 100% contrast (10 ml contrast), mixed contrast solution (8:2 contrast/saline), and layered contrast below saline (“Parfait”) in different volumes. Contrast media were injected at room temperature (20°C) and after heating (37°C). Four operators injected 10 ml syringes filled with different mediums through 5-French angiographic catheters. The average flow rate was used to compare different contrast injection mediums. The Kruskal-Wallis test with post-hoc pairwise comparisons using Bonferroni correction or Mann-Whitney U-tests were employed depending on the type of comparison. Results Compared to the 100% contrast solution, every Parfait media and mixed contrast solution demonstrated significantly higher flow rates (p < 0.001). The 5 ml saline Parfait had the highest flow rate among the Parfait solutions. The 5 ml saline Parfait and the mixed solution had comparable flow rates (p = 0.237). Higher flow rates were observed upon heating both 100% contrast (p < 0.001) and mixed contrast solutions (p < 0.001) in comparison to their flow rates at room temperature. Conclusion This study demonstrates the capability of the Parfait and mixed contrast injections to achieve higher flow rates than the 100% contrast solutions. Heating the contrast media to 37°C also proves to be a viable strategy for further enhancing the flow rates for 100% and mixed contrast solutions.
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
Seiffge, David , Group, STR-OAC LAAO, Macha, Kosmas , Takagi, Masahito, Arihiro, Shoji , Polymeris, Alexandros A. , Yoshimura, Sohei , Venti, Michele , Thilemann, Sebastian , Altavilla, Riccardo , Peters, Nils , Inoue, Manabu, Bobinger, Tobias , Agnelli, Giancarlo , Acciarresi, Monica, Jager, Hans, Bovi, Paolo, Schwab, Stefan , Registry, RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen Registry, and Verona, Aarnink, Errol W. , Fierro, Nicolai, Tondo, Claudio , Zieliński, Kamil , Korsholm, Kasper , Nielsen-Kudsk, Jens Erik, Caneiro‐Queija, Berenice, Benito‐González, Tomás , Holmes, David R. , Almakadma, Abdul H., Álvarez, Xavier Millán, Alla, Venkata , Agarwal, Himanshu , Paitazoglou, Christina , Freixa, Xavier , Cepas‐Guillén, Pedro , Chothia, Rashaad , Badejoko, Solomon O. , Bergmann, Martin , Spoon, Daniel B., Maddux, James T., Ram, Pradhum , Branca, Luca , Dijk, Vincent F. van , Rensing, Benno J. , Paciaroni, Maurizio , Kallmünzer, Bernd , Wilson, Duncan , Jäger, Hans Rolf , Korsholm, Kasper , Seiffge, David , Jäger, Hans Rolf , Cepas-Guillen, Pedro , Maarse, Moniek , Werring, David J. , Boersma, Lucas V.A. , Group, STR-OAC LAAO, Tsivgoulis, Georgios , Bonetti, Bruno , Alberti, Andrea , Ambler, Gareth , Bonati, Leo H. , Muir, Keith W. , Yamagami, Hiroshi, Inoue, Manabu , Brown, Martin M. , Sato, Shoichiro , Lyrer, Philippe A. , Marchis, Gian Marco De , Peper, Joyce , Simard, Trevor , Alkhouli, Mohamad , Registry, RAF, RAF-DOAC, CROMIS-2, SAMURAI, NOACISP, Erlangen Registry, and Verona, Mazzone, Patrizio , Beneduce, Alessandro , Gasperetti, Alessio , Pracoń, Radosław , Demkow, Marcin , Backer, Ole De , Nielsen‐Kudsk, Jens Erik , Estévez‐Loureiro, Rodrigo , Prado, Armando Pérez de , Nombela‐Franco, Luis , Salinas, Pablo , Berti, Sérgio , Romeo, Maria Rita , Arzamendi, Dabit , Eitel, Ingo , Bergmann, Martin W., El‐Chami, Mikhael F. , Adamo, Marianna , Suradi, Hussam , Zietz, Annaelle , Caso, Valeria , Koga, Masatoshi , Toyoda, Ḱazunori , Cappellari, Manuel , Engelter, Stefan T. , Swaans, Martin John

Mayo Clinic

JAMA Neurology | September 23, 2024 | Volume: 81 | Issue: 11 | Pages: 1150

10.1001/jamaneurol.2024.2882 | PMID 39374446 Get It

ImportancePatients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT.ObjectiveTo compare percutaneous LAAO with continuing OAT alone regarding stroke prevention in patients with AF who had a thromboembolic event despite taking OAT.Design, Setting, and ParticipantsThis cohort study was a propensity score–matched comparison of the STR-OAC LAAO cohort, an international collaboration of 21 sites combining patients from multiple prospective registries of patients who underwent LAAO between 2010 and 2022. STR-OAC LAAO cohort patients who had follow-up longer than 3 months were propensity score–matched to a previously published control cohort comprising patients from an established international collaboration of investigator-initiated prospective studies. This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient ischemic attack, and follow-up longer than 3 months who were taking OAT before the index event. Analyses were adjusted for imbalances in gender, age, hypertension, diabetes, and CHA2 DS2-VASc score.ExposureLeft atrial appendage occlusion vs continuation of oral anticoagulation therapy alone (control group).Main Outcomes and MeasuresThe primary outcome was time to first ischemic stroke.ResultsFour hundred thirty-three patients from the STR-OAC LAAO cohort (mean [SD] age, 72 [9] years; 171 [39%] females and 262 [61%] males; mean [SD] CHA2 DS2-VASc score, 5.0 [1.6]) were matched to 433 of 1140 patients (38%) from the control group. During 2-year follow-up, 50 patients experienced ischemic stroke: an annualized event rate of 2.8% per patient-year in the STR-OAC LAAO group vs 8.9% per patient-year in the control group. Left atrial appendage occlusion was associated with a lower risk of ischemic stroke (hazard ratio, 0.33; 95% CI, 0.19-0.58; P &amp;lt; .001) compared with the control group. After LAAO, OAT was discontinued in 290 patients (67%), and the remaining 143 patients (33%) continued OAT after LAAO as an adjunctive therapy.Conclusions and RelevanceIn patients with nonvalvular AF and a prior thromboembolic event despite taking OAT, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone. Randomized clinical trial data are needed to confirm that LAAO may be a promising treatment option for this population with a very high risk of stroke.
Language-model-based patient embedding using electronic health records facilitates phenotyping, disease forecasting, and progression analysis
Su, Xian , Grabowska, Monika E. , Kullo, Iftikhar J. , Luo, Yuan , Wei, Wei‐Qi, Crosslin, David R. , Xian, Su , Wei, Wei-Qi , Kullo, Iftikhar J , Luo, Yuan , Smoller, Jordan W. , Jarvik, Gail P. , Mooney, Sean D.

Mayo Clinic

No container title available | September 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4708839/v1 | PMID 39399661 Get It

Abstract Current studies regarding the secondary use of electronic health records (EHR) predominantly rely on domain expertise and existing medical knowledge. Though significant efforts have been devoted to investigating the application of machine learning algorithms in the EHR, efficient and powerful representation of patients is needed to unleash the potential of discovering new medical patterns underlying the EHR. Here, we present an unsupervised method for embedding high-dimensional EHR data at the patient level, aimed at characterizing patient heterogeneity in complex diseases and identifying new disease patterns associated with clinical outcome disparities. Inspired by the architecture of modern language models—specifically transformers with attention mechanisms, we use patient diagnosis and procedure codes as vocabularies and treat each patient as a sentence to perform the patient embedding. We applied this approach to 34,851 unique medical codes across 1,046,649 longitudinal patient events, including 102,739 patients from the electronic Medical Records and GEnomics (eMERGE) Network. The resulting patient vectors demonstrated excellent performance in predicting future disease events (median AUROC = 0.87 within one year) and bulk phenotyping (median AUROC = 0.84). We then illustrated the utility of these patient vectors in revealing heterogeneous comorbidity patterns, exemplified by disease subtypes in colorectal cancer and systemic lupus erythematosus, and capturing distinct longitudinal disease trajectories. External validation using EHR data from the University of Washington confirmed robust model performance, with median AUROCs of 0.83 and 0.84 for bulk phenotyping tasks and disease onset prediction, respectively. Importantly, the model reproduced the clustering results of disease subtypes identified in the eMERGE cohort and uncovered variations in overall mortality among these subtypes. Together, these results underscore the potential of representation learning in EHRs to enhance patient characterization and associated clinical outcomes, thereby advancing disease forecasting and facilitating personalized medicine.